Cantheon Capital

Oxford Cannabinoid Technologies Ltd., established in 2017 and based in Oxford, UK, is a biopharmaceutical company dedicated to researching, developing, and licensing cannabinoid-based compounds and therapies. Its primary focus lies in creating novel treatments for diseases with high unmet medical need, combining cannabinoid medicine with world-class scientific research and drug development. The company's therapeutic areas of interest include inflammatory diseases, oncology, neurological disorders, and pain management.

Zelira Therapeutics Limited is a bio-pharmaceutical company based in Perth, Australia, specializing in the development of cannabinoid-based formulations aimed at treating various medical conditions. The company conducts human clinical trials targeting insomnia, autism, and opioid reduction, while also engaging in pre-clinical research to explore the effects of cannabinoids on breast, brain, and pancreatic cancers. Additionally, Zelira is investigating the potential of cannabinoid formulations to address diabetes-associated cognitive decline. The company collaborates with CannPal Pty Ltd and St Vincent's Hospital on opioid reduction studies. Formerly known as Zelda Therapeutics Limited, it rebranded to Zelira Therapeutics Limited in December 2019.